Merus N.V (MRUS) Company Profile & Statistics

Merus N.V
MRUS
(Nasdaq - US)
Open
44.85
-1.73 (-3.71%)
in:usd•As of: Nov 18, 2024 12:23 UTC -5
Open
46.51
High
46.58
Low
44.79

About Merus N.V

CEO

Sven (Bill) Ante Lundberg

Headquarters

uppsalalaan 17

utrecht, p7 3584, netherlands

Auditor

KPMG Accountants N.V.

Employees

229

Share Holders

190

Website

www.merus.nl

Industry

biotechnology

Sector

health technology

Company Overview

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

Merus N.V Statistics

Valuation Measures

Market Capitalization ²	3.07B
Enterprise Value	2.64B
Enterprise Value/EBITDA (ttm)	-11.54
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	4.53
Price to Sales (ttm)	88.75
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-583.34%
Profit Margin (ttm)	-660.22%
Return on Equity (ttm)	-38.89%
Return on Invested Capital (ttm)	-47.65%
Return on Assets (ttm)	-31.16%

Income Statement

Revenue (ttm)	35.93M
Revenue Per Share (ttm)	0.52
Gross Profit (ttm)	35.93M
EBITDA (ttm)³	-228.46M
Net Income Avi to Common (ttm)	-244.56M
Diluted EPS (ttm)	-3.95

Share Statistics

Beta (5Y Monthly)	1.12
52-Week Change	84.57%
S&P500 52-Week Change	29.59%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	68.46M
Dividend Yield	0.00%
Float ⁴	65.33M
% Held by Insiders	4.57%
% Held by Institutions	96.14%

Balance Sheet

Total Cash (mrq)	632.27M
Total Cash Per Share (mrq)	9.24
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	8.32%
Quick Ratio (mrq)	8.32%
Book Value Per Share (mrq)	10.28

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.75
Free Cash Flow (ytd)	-120.82M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Merus N.V

Trade With A Regulated Broker